Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03139435 · ClinicalTrials.gov registry record · NA
Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03139435 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT03139435, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.
Interventions
- PROCEDURE Biopsy
- OTHER Questionnaire Administration
- DIAGNOSTIC_TEST Ultrasound Tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2019-01-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03139435
The ClinicalTrials.gov registry entry for NCT03139435 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Biopsy is the first listed.
NCT03139435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03139435 about?
NCT03139435 is a clinical study titled "Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer". This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.
What is the current status of trial NCT03139435?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-05-11. Estimated completion is 2019-01-11.
What interventions are being tested in trial NCT03139435?
The interventions under investigation include: Biopsy (PROCEDURE), Questionnaire Administration (OTHER), Ultrasound Tomography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03139435?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.